Radiopharm says targeted therapy demonstrates potential for pancreatic cancer patients

November 18, 2024 News

This is a preview of subscriber content

Subscribe now to continue reading.

Clinical-stage nuclear medicine company Radiopharm Theranostics (ASX:RAD) has announced the publication of positive results of a retrospective study of the biokinetics of 68Ga-RAD 301 in pancreatic cancer patients. …

Subscribe now to continue reading.

Latest Video

New Stories

NDIS keeps growing but signs emerge that reforms are starting to work
July 17, 2025 - - Latest News
USTR launches new investigation, with minimal ambition on pharmaceuticals
July 17, 2025 - - Latest News
New Zealand starting to benefit after lifting advertising prohibition
July 17, 2025 - - Latest News
Mark Butler restates support for health technology assessment reform
July 16, 2025 - - Latest News
Brandon BioCatalyst welcomes the inclusion of its CUREator in new program
July 16, 2025 - - Australian Biotech
Cancer Australia launches research program targeting early-onset cancers
July 16, 2025 - - Latest News
Imugene completes significant placement and launches share purchase plan
July 16, 2025 - - Australian Biotech

Radiopharm says targeted therapy demonstrates potential for pancreatic cancer patients

This is a preview of subscriber content

Latest Video

Most Read

HTA reform is fine, but why is the underpinning framework immutable?

Olympian joins call urging vigilance on meningococcal risk

Patient Voice Initiative announces the appointment of new president

The need to correct a profound misconception of what ethical decision-making is and is not

New Australian collaboration to build gene and cell therapy production

New Stories

NDIS keeps growing but signs emerge that reforms are starting to work

USTR launches new investigation, with minimal ambition on pharmaceuticals

New Zealand starting to benefit after lifting advertising prohibition

Mark Butler restates support for health technology assessment reform

Brandon BioCatalyst welcomes the inclusion of its CUREator in new program

Cancer Australia launches research program targeting early-onset cancers

Imugene completes significant placement and launches share purchase plan

Sign In

Radiopharm says targeted therapy demonstrates potential for pancreatic cancer patients

This is a preview of subscriber content

Latest Video

Most Read

HTA reform is fine, but why is the underpinning framework immutable?

Olympian joins call urging vigilance on meningococcal risk

Patient Voice Initiative announces the appointment of new president

The need to correct a profound misconception of what ethical decision-making is and is not

New Australian collaboration to build gene and cell therapy production

Follow Us

New Stories

NDIS keeps growing but signs emerge that reforms are starting to work

USTR launches new investigation, with minimal ambition on pharmaceuticals

New Zealand starting to benefit after lifting advertising prohibition

Mark Butler restates support for health technology assessment reform

Brandon BioCatalyst welcomes the inclusion of its CUREator in new program

Cancer Australia launches research program targeting early-onset cancers

Imugene completes significant placement and launches share purchase plan